Safety and preliminary activity of neoadjuvant trastuzumab deruxtecan (T-DXd) plus 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma: Results from the safety run-in cohort of the phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trial
{{output}}
Introduction: Despite advances in the multimodal treatment of resectable esophagogastric adenocarcinoma (EGA), relapse rates remain high. No human epidermal growth factor receptor 2 (HER2)-targeted treatment is yet established in... ...
